Author

M. Ramachandra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Chinnaiyan· 1 shared A. Parolia· 1 shared A. Pellagatti· 1 shared A. Shastri· 1 shared A. Verma· 1 shared A. Wickrema· 1 shared B. Agianian· 1 shared B. Will· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Chinnaiyan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies

T. He, L. Xiao, Y. Qiao, O. Klingbeil, E. Young, X. S. Wu, R. Mannan, S. Mahapatra, S. Eyunni, J. C.-Y. Tien, X. Wang, Y. Zheng, N. Kim, H. Zheng, S. Hou, , A. M. Chinnaiyan

This study identifies a therapeutic vulnerability in POU2F-POU2AF-driven cancers by showing that targeting the mSWI/SNF complex with a PROTAC degrader reduces tumor growth in preclinical models.

bioRxiv · Jan 22, 2024Cancer Biology

Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutations

G. Choudhary, A. Pellagatti, B. Agianian, M. Smith, T. D. Bhagat, S. Gordon-Mitchell, S. Pandey, N. Shah, S. Aluri, L. Schwartz, V. Steeples, R. Booher, M. Ramachandra, M. Samson, M. Carbajal, , A. Verma

This study identifies a longer, oncogenic IRAK4 isoform caused by SF3B1 mutations in MDS/AML, which is targetable by IRAK4 inhibition.

bioRxiv · Mar 9, 2022Cancer Biology